Cargando…

Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines

Gemcitabine and paclitaxel are active agents in the treatment of non-small-cell lung cancer (NSCLC). To optimize treatment drug combinations, simultaneously and 4 and 24 h intervals, were studied using DNA flow cytometry and multiple drug effect analysis in the NSCLC cell lines H460, H322 and Lewis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroep, J R, Giaccone, G, Tolis, C, Voorn, D A, Loves, W J P, Groeningen, C J van, Pinedo, H M, Peters, G J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363564/
https://www.ncbi.nlm.nih.gov/pubmed/10993656
http://dx.doi.org/10.1054/bjoc.2000.1399
_version_ 1782153736220573696
author Kroep, J R
Giaccone, G
Tolis, C
Voorn, D A
Loves, W J P
Groeningen, C J van
Pinedo, H M
Peters, G J
author_facet Kroep, J R
Giaccone, G
Tolis, C
Voorn, D A
Loves, W J P
Groeningen, C J van
Pinedo, H M
Peters, G J
author_sort Kroep, J R
collection PubMed
description Gemcitabine and paclitaxel are active agents in the treatment of non-small-cell lung cancer (NSCLC). To optimize treatment drug combinations, simultaneously and 4 and 24 h intervals, were studied using DNA flow cytometry and multiple drug effect analysis in the NSCLC cell lines H460, H322 and Lewis Lung. All combinations resulted in comparable cytotoxicity, varying from additivity to antagonism (combination index: 1.0–2.6). Gemcitabine caused a S (48%) and G1 (64%) arrest at IC-50 and 10 × IC-50 concentrations, respectively. Paclitaxel induced G2/M arrest (70%) which was maximal within 24 h at 10 × IC-50. Simultaneous treatment increased S-phase arrest, while at the 24 h interval after 72 h the first drug seemed to dominate the effect. Apoptosis was more pronounced when paclitaxel preceded gemcitabine (20% for both intervals) as compared to the reverse sequence (8%, P = 0.173 for the 4 h and 12%, P = 0.051 for the 24 h time interval). In H460 cells, paclitaxel increased 2-fold the accumulation of dFdCTP, the active metabolite of gemcitabine, in contrast to H322 cells. Paclitaxel did not affect deoxycytidine kinase levels, but ribonucleotide levels increased possibly explaining the increase in dFdCTP. Paclitaxel did not affect gemcitabine incorporation into DNA, but seemed to increase incorporation into RNA. Gemcitabine almost completely inhibited DNA synthesis in both cell lines (70–89%), while paclitaxel had a minor effect and did not increase that of gemcitabine. In conclusion, various gemcitabine–paclitaxel combinations did not show sequence dependent cytotoxic effects; all combinations were not more than additive. However, since paclitaxel increased dFdCTP accumulation, gemcitabine incorporation into RNA and the apoptotic index, the administration of paclitaxel prior to gemcitabine might be favourable as compared to reversed sequences. © 2000 Cancer Research Campaign
format Text
id pubmed-2363564
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23635642009-09-10 Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines Kroep, J R Giaccone, G Tolis, C Voorn, D A Loves, W J P Groeningen, C J van Pinedo, H M Peters, G J Br J Cancer Regular Article Gemcitabine and paclitaxel are active agents in the treatment of non-small-cell lung cancer (NSCLC). To optimize treatment drug combinations, simultaneously and 4 and 24 h intervals, were studied using DNA flow cytometry and multiple drug effect analysis in the NSCLC cell lines H460, H322 and Lewis Lung. All combinations resulted in comparable cytotoxicity, varying from additivity to antagonism (combination index: 1.0–2.6). Gemcitabine caused a S (48%) and G1 (64%) arrest at IC-50 and 10 × IC-50 concentrations, respectively. Paclitaxel induced G2/M arrest (70%) which was maximal within 24 h at 10 × IC-50. Simultaneous treatment increased S-phase arrest, while at the 24 h interval after 72 h the first drug seemed to dominate the effect. Apoptosis was more pronounced when paclitaxel preceded gemcitabine (20% for both intervals) as compared to the reverse sequence (8%, P = 0.173 for the 4 h and 12%, P = 0.051 for the 24 h time interval). In H460 cells, paclitaxel increased 2-fold the accumulation of dFdCTP, the active metabolite of gemcitabine, in contrast to H322 cells. Paclitaxel did not affect deoxycytidine kinase levels, but ribonucleotide levels increased possibly explaining the increase in dFdCTP. Paclitaxel did not affect gemcitabine incorporation into DNA, but seemed to increase incorporation into RNA. Gemcitabine almost completely inhibited DNA synthesis in both cell lines (70–89%), while paclitaxel had a minor effect and did not increase that of gemcitabine. In conclusion, various gemcitabine–paclitaxel combinations did not show sequence dependent cytotoxic effects; all combinations were not more than additive. However, since paclitaxel increased dFdCTP accumulation, gemcitabine incorporation into RNA and the apoptotic index, the administration of paclitaxel prior to gemcitabine might be favourable as compared to reversed sequences. © 2000 Cancer Research Campaign Nature Publishing Group 2000-10 /pmc/articles/PMC2363564/ /pubmed/10993656 http://dx.doi.org/10.1054/bjoc.2000.1399 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Kroep, J R
Giaccone, G
Tolis, C
Voorn, D A
Loves, W J P
Groeningen, C J van
Pinedo, H M
Peters, G J
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
title Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
title_full Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
title_fullStr Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
title_full_unstemmed Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
title_short Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
title_sort sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363564/
https://www.ncbi.nlm.nih.gov/pubmed/10993656
http://dx.doi.org/10.1054/bjoc.2000.1399
work_keys_str_mv AT kroepjr sequencedependenteffectofpaclitaxelongemcitabinemetabolisminrelationtocellcycleandcytotoxicityinnonsmallcelllungcancercelllines
AT giacconeg sequencedependenteffectofpaclitaxelongemcitabinemetabolisminrelationtocellcycleandcytotoxicityinnonsmallcelllungcancercelllines
AT tolisc sequencedependenteffectofpaclitaxelongemcitabinemetabolisminrelationtocellcycleandcytotoxicityinnonsmallcelllungcancercelllines
AT voornda sequencedependenteffectofpaclitaxelongemcitabinemetabolisminrelationtocellcycleandcytotoxicityinnonsmallcelllungcancercelllines
AT loveswjp sequencedependenteffectofpaclitaxelongemcitabinemetabolisminrelationtocellcycleandcytotoxicityinnonsmallcelllungcancercelllines
AT groeningencjvan sequencedependenteffectofpaclitaxelongemcitabinemetabolisminrelationtocellcycleandcytotoxicityinnonsmallcelllungcancercelllines
AT pinedohm sequencedependenteffectofpaclitaxelongemcitabinemetabolisminrelationtocellcycleandcytotoxicityinnonsmallcelllungcancercelllines
AT petersgj sequencedependenteffectofpaclitaxelongemcitabinemetabolisminrelationtocellcycleandcytotoxicityinnonsmallcelllungcancercelllines